A notable advancement in diabetes care is emerging with the approval of tirzepatide at a dosage of 45mg. This innovative formulation builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://elodieijdc481637.wikilowdown.com/7624051/significant_development_tirzepatide_dose_for_glucose_management